Skip to content

Study · Non-randomized trial · n = 24 · 2025

4 results

Plasma pharmacokinetics of intravenous and intranasal oxytocin in nonpregnant adults.

Shafer SL, Ririe DG, Miller S, Curry RS, Hsu DT, Sullivan GM, Eisenach JC

British journal of anaesthesia21 Mar 2025Cited by 6 (Europe PMC)

PMID40121179 (opens in a new tab)PMCIDPMC12106900 (opens in a new tab)DOI10.1016/j.bja.2024.12.046 (opens in a new tab)PepBankPUB-40121179
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy adults, a two-compartment model for intranasal oxytocin showed substantial subject-to-subject variability (9% median bias, 47% median inaccuracy).

    In plain wordsIn healthy adults, blood levels after nasal oxytocin varied a lot from person to person.

    Peptide
    Oxytocin
    Outcome
    Not applicableIntranasal oxytocin population pharmacokinetic model
    Study

    n = 24

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 µg · intranasalAs given in this study (human).

    Measurements

    median bias
    9%
    intranasal model
    median inaccuracy
    47%
    intranasal model

    Source sentences

    Summary
    The two-compartment model for intranasal oxytocin was characterised by substantial subject-to-subject variability (9% median bias, 47% median inaccuracy).
    1 context sentence
    Summary · context
    Two studies in healthy adult men and nonpregnant women were performed, the first with intravenous oxytocin 16.7 μg over 1 or 10 min and the second with intravenous oxytocin 13.7 μg over 30 min and, on a separate day, intranasal oxytocin 100 μg (n=24).
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy adults, intranasal oxytocin bioavailability was 0.7%.

    In plain wordsIn healthy adults, only a very small share of nasal oxytocin reached the blood.

    Peptide
    Oxytocin
    Outcome
    Not applicableIntranasal oxytocin bioavailability
    Study

    n = 24

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 µg · intranasalAs given in this study (human).

    Measurements

    bioavailability
    0.7%
    intranasal

    Source sentences

    Summary
    Nasal oxytocin bioavailability was 0.7%.
    1 context sentence
    Summary · context
    Two studies in healthy adult men and nonpregnant women were performed, the first with intravenous oxytocin 16.7 μg over 1 or 10 min and the second with intravenous oxytocin 13.7 μg over 30 min and, on a separate day, intranasal oxytocin 100 μg (n=24).
  3. 03HumanNon-randomized trialPharmacokinetics

    In healthy adults, intravenous oxytocin pharmacokinetics were well described by a two-compartment model with 0% bias and 18% median inaccuracy.

    In plain wordsIn healthy adults, a two-compartment model described how the body handles intravenous oxytocin well.

    Peptide
    Oxytocin
    Outcome
    Not applicableIntravenous oxytocin population pharmacokinetic model
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    16.7 µg over 1 or 10 min; 13.7 µg over 30 min · intravenousAs given in this study (human).

    Measurements

    median bias
    0%
    intravenous model
    median inaccuracy
    18%
    intravenous model

    Source sentences

    Summary
    The pharmacokinetics of intravenous oxytocin were well described by a two-compartment model (0% bias, 18% median inaccuracy).
    1 context sentence
    Summary · context
    Two studies in healthy adult men and nonpregnant women were performed, the first with intravenous oxytocin 16.7 μg over 1 or 10 min and the second with intravenous oxytocin 13.7 μg over 30 min and, on a separate day, intranasal oxytocin 100 μg (n=24).

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 04HumanNot a test of Oxytocin aloneNon-randomized trialOther

    In plasma samples from healthy adults, LC/MS gave systematically higher oxytocin values than simultaneous ELISA samples.

    In plain wordsIn blood samples from healthy adults, the mass spectrometry test gave higher oxytocin readings than the antibody test.

    Peptide
    Oxytocin
    Outcome
    Not applicableOxytocin concentrations by LC/MS versus ELISA
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Oxytocin samples assayed with LC/MS were systematically higher than simultaneous samples assayed with enzyme-linked immunosorbent assay.
    1 context sentence
    Summary · context
    Two studies in healthy adult men and nonpregnant women were performed, the first with intravenous oxytocin 16.7 μg over 1 or 10 min and the second with intravenous oxytocin 13.7 μg over 30 min and, on a separate day, intranasal oxytocin 100 μg (n=24).

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1Results postedNCT05672667

A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects

Wake Forest University Health Sciencesn = 2527 Feb 2023 to 1 Nov 2023

Healthy Volunteer Study

Trial pageClinicalTrials.govUpdated 17 Feb 2025
CompletedPhase 4Results postedNCT03929367

PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers

Wake Forest University Health Sciencesn = 1110 May 2019 to 1 Mar 2020

Chronic Pain

Trial pageClinicalTrials.govUpdated 13 May 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.